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Abstract
Methylation-based non-invasive prenatal testing of fetal aneuploidies is an alternative
method that could possibly improve fetal aneuploidy diagnosis, especially for trisomy 13
(T13) and trisomy 18(T18). Our aim was to study the methylation landscape in placenta
DNA from trisomy 13, 18 and 21 pregnancies in an attempt to find trisomy–specific methyla-
tion differences better suited for non-invasive prenatal diagnosis. We have conducted high-
resolution methylation specific bead chip microarray analyses assessing more than
450,000 CpGs analyzing placentas from 12 T21 pregnancies, 12 T18 pregnancies and 6
T13 pregnancies. We have compared the methylation landscape of the trisomic placentas
to the methylation landscape from normal placental DNA and to maternal blood cell DNA.
Comparing trisomic placentas to normal placentas we identified 217 and 219 differentially
methylated CpGs for CVS T18 and CVS T13, respectively (delta β>0.2, FDR<0.05), but
only three differentially methylated CpGs for T21. However, the methylation differences was
only modest (delta β<0.4), making them less suitable as diagnostic markers. Gene ontology
enrichment analysis revealed that the gene set connected to theT18 differentially methyl-
ated CpGs was highly enriched for GO terms related to”DNA binding” and “transcription fac-
tor binding” coupled to the RNA polymerase II transcription. In the gene set connected to
the T13 differentially methylated CpGs we found no significant enrichments.
Introduction
Achieving non-invasive prenatal diagnosis of fetal cases of the common chromosome aneu-
ploidies based on circulating free fetal DNA (cffDNA) in maternal plasma has for more than a
decade been the goal of many research groups. The overall strategy for this research was to
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achieve sufficiently precise quantitation of e.g. chromosome 21 DNA fragments compared to
fragments from a reference chromosome, so that a significant rise in chromosome 21 DNA
fragments in maternal plasma could be demonstrated in pregnancies carrying a fetus with tri-
somy 21 (T21).
One approach to accomplish this is to measure circulating free DNA (cfDNA) in maternal
blood with sufficient precision to demonstrate a significantly increased amount of e.g. chromo-
some 21 derived fragments, even when measuring the substantial background of maternal
DNA fragments. This strategy has turned out to be successful for T21 when the quantitation is
performed by Next generation sequencing (NGS). However, even though NGS has proven
effective for T21 testing there are still problems with reliable demonstration of trisomy 13
(T13) and trisomy 18 (T18) with this approach[1]. Furthermore, the ability to detect increased
chromosome dosage is very dependent on cffDNA fraction resulting in a minor fraction of
non-reportable results.
An alternative approach to improve the method could be to obtain fetal DNA specificity by
preferentially targeting fetal DNA sequences in the quantitative analysis. Thereby, likely lower-
ing the limitation coming from the sensibility to low cffDNA fraction. This has been tried by
several groups utilizing features such as DNA fragment length or epigenetic signatures, to dis-
tinguish the fetally derived DNA from the huge excess of maternal DNA [2–6]. In this context,
we have in a previous study, using full genome methylation arrays, compared the methylation
status of DNA from 12 placenta samples to DNA from 10 maternal blood samples, all from
pregnancies in the first trimester [7]. We identified highly placenta specific epigenetic markers
located on chromosome 13, 18, and 21 as well as highly placenta specific epigenetic markers in
the regions of several microdeletion syndromes.
An alternative way to improve the discrimination between fetal and maternal cfDNA for
non-invasive prenatal testing (NIPT) of the fetal aneuploidies would be to define fetal markers
that are not only placenta specific but specific for trisomic placental DNA, preferable in the
form of methylation differences. In agreement with this theory, two recent studies have looked
into general epigenetic patterns in placental DNA from T21 cases and observed a general
hypermethylation in T21 placentas compared to normal placentas [8,9]. We therefore extended
our previous study by investigating the methylation landscape in placental DNA from the
three common aneuploidies T21, T13, and T18 and compared it to the methylation landscape
in DNA from normal placentas and from maternal blood cell (MBC) DNA in an attempt to
demonstrate possible methylation differences better suited for NIPT especially for T13 and
T18.
We have in addition looked into possible biological relevance of sites that differed in meth-
ylation between DNA from normal and trisomic placenta samples, firstly by characterizing the
location of such sites within or between CpG islands and secondly by looking at the biological
function of genes closest to the candidate sites using gene ontology.
Materials and Methods
Clinical samples
All the samples for the microarray study were sampled from 1st trimester pregnant women,
who underwent chorionic villus sampling (CVS) due to increased risk of T21, T18 or T13, esti-
mated by a combination of the nuchal translucency testing and the double test (measuring the
plasma protein markers; Pregnancy Associated Plasma Protein A (PAPP-A) and Chorionic
Gonadotropin Beta (free β-hCG). We used 12 CVS samples from T21 pregnancies, 12 CVS
samples from T18 pregnancies and 6 CVS samples from T13 pregnancies, all verified by chro-
mosome analysis on CVS samples. We further used the data from our recent study [7] where
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we analyzed 12 CVS samples from normal pregnancies and 10 blood samples, from 1st trimes-
ter pregnant women with a normal fetus, judged by a normal karyotype on CVS. An overview
of all the samples including gestational age, maternal age and year of sampling can be viewed
in the supporting information, S1 Table.
The project was approved by The Regional Committee on Health Research Ethics and The
Regional Scientific Ethical Committees for Southern Denmark (Project no: S-20120042). The
material used was excess DNA from routine investigation, stored at the biobank at the Clinical
Genetic Department at Vejle Hospital. The samples were anonymized and de-identified prior
to analysis. The institutional board at the Department of Clinical Genetics and The Regional
Scientific Ethical Committees for Southern Denmark therefore waived the need for written
informed consent for this study.
Processing of samples was done under identical conditions, however not all at the same
time. The samples were not blinded.
DNA extraction and quantification
Blood samples. DNA from blood samples were extracted using a standard salt extraction
method as described in our previous study [7]
CVS samples. DNA from CVS samples was extracted using a QIAamp DNAMini kit
from Qiagen (QIAGEN Inc., Valencia, CA, USA) according to standard protocol provided by
Qiagen. The samples were analyzed after separation of maternal decidua and without cell
culture.
DNAQuantification
DNA samples were quantified with a Nanodrop ND-1000 (Nanodrop Technologies, Wilming-
ton, DE, USA)
DNAmethylation analysis–Infinium microarray analysis
The Illumina Infinium HumanMethylation450 Beadchip Kit (Illumina Inc., San Diego, CA,
USA) was utilized for generation of methylation data for all samples. The analysis was done
according to standard protocol provided by Illumina. Bisulfite conversion was done using a
Zymo Research EZ DNAmethylation kit (Zymo Research, Irvine, CA, USA). Beadchips were
scanned with an Illumina HiScanSQ scanner using standard settings. Initial quality control,
background subtraction and raw data normalization were done using the standard algorithms
provided in Illumina Genome studio Methylation module v1.0. Methylation levels are quanti-
fied using β-values, as recommended by Illumina. Briefly, the β-value for each interrogated
CpG site represents the fraction of methylated versus non-methylated probes, and conse-
quently, the β-value ranges from 0 (unmethylated) to 1 (fully methylated). All analysis and sta-
tistical testing was performed on β-values.
Data quality
The Infinium arrays include several control probes for determining data quality, including
bisulphite conversion controls. Diagnostic plots of all control probes were visually inspected in
the Genome studio software for the approval of each of our arrays. We have added the quality
control plots in supporting information(S2 Fig).
Furthermore, 4 samples were analyzed in duplicates on different bead chip arrays. These
replicates were analyzed to ensure reproducible data. Methylation data from the different
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beadchip showed very strong correlation between replicates (r>0.99). Validation data for the
reproducibility of the 4 replicates can be viewed in S3–S5 Figs and S3 Table.
In addition, the microarray beadchip encompasses 65 probes for highly polymorphic single
nucleotide polymorphisms (SNPs). When comparing the 65 polymorphic probes (correspond
to genotype) between replicates, the status for each of these 65 sites was highly comparable
between replicates (Spearman rho for each pair of replicates; 0.96 to 0.98). β-value of 0.0, 0.5,
and 1.0 showed clear distinct patterns of homozygous or heterozygous methylation(Scatterplot
of the correlation can be viewed in S6 Fig)
Bioinformatics
Prefiltering and analysis of identified differentially methylated CpGs (DMCs) was performed
as previously described [7], for all methylation profiles. In short, differences in methylation sta-
tus between sample groups (e.g. CNOR vs T13) were evaluated for each CpG-site using the
non-parametric Wilcoxon signed-rank test. The P-values were subsequently adjusted for mul-
tiple hypotheses testing using Benjamini-Hochberg correction. The resulting false discovery
rates (FDRs) were used in combination with a Δβ-value cut-off (i.e. a minimum required differ-
ence in methylation level) between sample group means to define differentially methylated
CpGs (DMCs). The addition of a Δβ-value cutoff in our definition of DMCs ensures that the
observed methylation differences between sample groups (e.g. between the CNOR samples and
the T13 samples), for a given CpG, is of a sufficient magnitude to be considered of biological
relevance. The full dataset has been deposited in the gene Expression Omnibus (GEO) database
(accession number GSE66210). In addition, the GOrilla web tool[10,11] was used for Gene
Ontology(GO) analyses. The target and background gene lists were obtained by assigning each
CpG to the nearest gene (RefSeq). Consequently, the GO analyses uses all genes represented
(i.e. nearest gene) on the 450K array as background, and a small subset based on identified
DMCs, as target list.
Results
General methylation landscape
First the general methylation landscape in the different groups was described. Maternal white
blood cells (MBCs) showed a very sharp and clear bimodal methylation distribution pattern
(Fig 1). Thus, 36% of the CpGs for MBCs were hypomethylated (β-value<0.2) and 39% were
hypermethylated (β-value>0.8, Table 1). The CVS samples also showed a somewhat bimodal
distribution for the methylation of the CpGs, but the methylation pattern was partially shifted
from hypermethylation to semimethylation. Hence, 35% of the CpG sites for normal diploid
(CVSNORM) were hypomethylated whereas only 16% were hypermethylated. The general meth-
ylation pattern observed for each of the trisomic CVS (T21, T18 and T13) closely resembled
that of the normal diploid CVS (CVSNORM), although minor changes in the fraction of hyper-
methylated sites was observed compared to CVSNORM (Table 1). Thus the fraction of hyper-
methylated sites for CVST21 was slightly increased (17.81%), whereas it was decreased for
CVST13 and CVST18 (13.96% and 12.64%, respectively). No major differences was observed in
the methylation pattern for individual chromosomes except for chromosome X in MBC sam-
ples, which is probably caused by a substantial methylation of one of the X-chromosomes due
to the X inactivation in females (S1 Fig).
Next we explored the methylation pattern of sites mapping to CpG-islands, CpG shores (2
kb flanking CpG islands), CpG-shelves (2kb flanking CpG shores) and open sea (CpGs not
mapping to islands, shores or shelves). In general, the methylation pattern of sites mapping to
each of these four regions is remarkably different with islands generally hypomethylated,
Microarray-Based Analysis of Methylation of 1st Trimester Trisomic Placentas
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shores bimodal methylated and shelves and open sea hypermethylated. In addition, placental
DNA is generally less hypermethylated (and concomitantly more semimethylated) for all four
regions, compared to MBC DNA (Fig 1).
Differences in CpGmethylation between DNA from MBCs, normal CVS
samples and trisomic CVS samples
Comparing the methylation profiles of MBC and CVSNORM revealed a huge number of DMCs
in agreement with the findings shown in Fig 1. When comparing CVSNORM to placental DNA
from the different trisomies, only 3 DMCs between CVSNORM and CVS T21 was identified,
whereas 217 and 219 DMCs was identified for CVS T18 and CVS T13, respectively (Table 2,
FDR<0.05). However, the mean difference in methylation level (β value) for CVS T18 and CVS
T13 DMCs was in the range 0.2 to ~0.4, suggesting that all of the identified DMCs represent
smaller methylation changes between placental DNA from normal and trisomic fetuses. Sur-
prisingly, only 6 DMC’s overlapped between CVS T18 and CVS T13.
Assessing the distribution of the DMCs in CVS T18, we found an enrichment of the DMCs
in CpG islands at the expense of shelves and open sea, when compared to the distribution of all
CpG sites (Fig 2). DMCs in CVS T13 were not enriched in any location. We also investigated
Table 1. CpGmethylation distribution.
Hypomethylated β < 0.2 Hypermethylated β > 0.8
Number of sites Percent Number of sites Percent
MBC 169392 35.89% 182223 38.61%
CVSNORM 164847 34.93% 77762 16.48%
CVS T21 158705 33.63% 84050 17.81%
CVS T13 163646 34.67% 65872 13.96%
CVS T18 164301 34.81% 59675 12.64%
The table lists the frequency of hypermethylated (mean β >0.8) and hypomethylation (mean β <0.2) CpG sites within each sample group. Maternal blood
cells (MBC), chorionic villus samples(CVS) from normal (CNOR), CVS T21, CVS T18 and CVS T13.
doi:10.1371/journal.pone.0160319.t001
Fig 1. Density plot.Methylation level distribution for all sites and for CpG-islands, CpG shores (2 kb flanking CpG islands), CpG-shelves
(2kb flanking CpG shores) and open sea (CpGs not mapping to islands, shores or shelves). X axis represents methylation level as mean β-
values. Y axis represents relative density. Maternal blood cells (MBC) red line, CVS normal blue line, CVS T13 black line, CVS T18 dark grey
line, T21 light grey line.
doi:10.1371/journal.pone.0160319.g001
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the distance of the CVS T18 DMCs to the transcription start site (TSS) for nearest gene, to see if
the enrichment in CpG island was related to promotor regions, however we did not find any
enrichment related to TSS.
Gene ontology of T18 and T13 DMCs
To get an impression of the biological functions of genes closest to the T13 and T18 DMCs,
Gene Ontology (GO) software was used. By associating each DMC to the nearest gene, the 219
CVS T13 and 217 CVS T18 DMCs were converted to gene-sets used for the GO-analyses. Only 3
DMCs was identified for T21, an inadequate number to establish a gene-set for a GO enrich-
ment analysis. The CVS T18 gene-set was highly enriched for several GO terms related to”DNA
binding” and “transcription factor binding” coupled to the RNA polymerase II transcription
(Table 3a). Table 3b lists the 10 most significant enrichments of molecular functions and bio-
logical processes for the CVS T18 DMCs. In contrast, not a single GO term was enriched for the
Table 2. Differential methylated CpGs (DMC)s.
Differentially methylated CpGs (DMC)
FDR MBC v CVSNORM T21 v CVSNORM T13 CVSNORM T18 CVSNORM
<0.05 143951 3 219 217
<0.01 143717 0 0 113
<0.001 142788 0 0 27
<0.0001 139494 0 0 0
The table lists the number of DMCs that hold a delta β >0.2 at different False Discovery Rate FDR. First column compares Maternal blood cells (MBC) to
normal CVS samples (CNOR). The following columns compare T21, 18, and 13 CVS samples to normal CVS, respectively.
doi:10.1371/journal.pone.0160319.t002
Fig 2. Stacked bar plot representation of the distribution of CpG sites. First column shows the distribution
of all the 471,956 investigated CpG sites on the microarray split into CpG Islands (black), Shores (dark grey)
Shelves (light grey) and open sea (White). Second and third columns show the distribution of sites that were
significantly higher methylated in T13 and T18 compared to normal CVS samples.
doi:10.1371/journal.pone.0160319.g002
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CVS T13 gene-set. The full list of enriched biological processes can be viewed in the supplemen-
tary material (S2 table).
Discussion
Using methylation array technology we have compared the methylation landscape between
MBC DNA and placental DNA and furthermore between normal placental DNA and placental
DNA from the three common trisomies, with the aim of exploring if these epigenetic differ-
ences could improve cffDNA-based non-invasive prenatal diagnosis (NIPD).
A clear difference in the overall methylation pattern between MBC DNA and all four types
of placental DNA was observed. Compared to DNA from maternal blood, CVS samples are
substantially less hyper-methylated (with a concomitant increased fraction of semi-methylated
sites), corroborating recent observations from two studies [9,12].
With regards to the trisomic samples, we observed that the fraction of fully methylated sites
were slightly increased in CVS T21 and decreased in CVS T13 and especially in CVS T18 com-
pared to CVSNORM. Exploring this closer by looking at number of sites that were significantly
Table 3. Gene Ontology(GO) analyses related to CVS T18 DMCs.
Table 3 A Molecular functions
GO Term Description FDR q-
value
Enrichment Genes within
GO-term
Tri18 genes
within GO-term
GO:0043565 sequence-speciﬁc DNA binding 2.50E-11 5.86 743 29
GO:0003677 DNA binding 2.14E-10 3.07 2346 48
GO:0000981 sequence-speciﬁc DNA binding RNA polymerase II transcription factor activity 1.27E-06 6.52 392 17
GO:0003700 sequence-speciﬁc DNA binding transcription factor activity 3.47E-06 3.77 1037 26
GO:0001071 nucleic acid binding transcription factor activity 2.83E-06 3.76 1038 26
GO:0003676 nucleic acid binding 4.86E-06 2.11 3770 53
GO:0044212 transcription regulatory region DNA binding 3.40E-05 4.93 518 17
GO:0000975 regulatory region DNA binding 3.61E-05 4.86 525 17
GO:0001067 regulatory region nucleic acid binding 3.21E-05 4.86 525 17
GO:0001228 RNA polymerase II transcription regulatory region sequence-speciﬁc DNA
binding transcription factor activity involved in positive regulation of transcription
4.12E-05 8.22 201 11
Table 3 B Biological processes
GO Term Description FDR q-
value
Enrichment Genes within
GO-term
Tri18 genes
within GO-term
GO:0045944 positive regulation of transcription from RNA polymerase II promoter 1.37E-07 4.71 861 27
GO:1903508 positive regulation of nucleic acid-templated transcription 5.72E-07 3.72 1170 29
GO:0019219 regulation of nucleobase-containing compound metabolic process 6.15E-07 2.12 4105 58
GO:0048518 positive regulation of biological process 6.22E-07 2.03 4585 62
GO:0045893 positive regulation of transcription, DNA-templated 6.35E-07 3.72 1170 29
GO:0045935 positive regulation of nucleobase-containing compound metabolic process 6.51E-07 2.96 1880 37
GO:0006357 regulation of transcription from RNA polymerase II promoter 6.63E-07 3.33 1487 33
GO:0006355 regulation of transcription, DNA-templated 6.79E-07 2.34 3216 50
GO:0051252 regulation of RNA metabolic process 6.91E-07 2.29 3340 51
GO:1903506 regulation of nucleic acid-templated transcription 6.99E-07 2.32 3240 50
GO:0051173 positive regulation of nitrogen compound metabolic process 7.01E-07 2.91 1907 37
A: Gene functions related to terms within the group “Molecular functions”. B. Gene functions related to terms within the group “Biological processes”. The
table shows the enrichment analysis for the genes associated to our DMCs in T18 samples. The total number of genes within the GO analysis is 17727. Our
gene set related to the CVS T18 DMCs were 118. Each table shows the 10 GO terms with the lowest False Discovery Rate (FDR q value).
doi:10.1371/journal.pone.0160319.t003
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different methylated in CVS T21, CVS T13 and CVS T18 DNA compared to CVSNORM DNA we
observed very few DMC’s in CVS T21 DNA and in contrast a substantial and very similar num-
ber of DMC’s for CVS T13 and CVS T18 DNA but with a very limited amount of overlap. The
DMC’s in T18 were more robust–lowering the FDR (increasing level of significance) lead to
clear differences between T18 and T13 (see Table 2). However, it should be remembered that
the sample sizes were different since, we could only include six T13 samples due to the rarity of
T13 pregnancies. We do not know the explicit reason as to why T13 and T18 have a higher
number of DMCs compared to T21, however it does coincide with the more severe phenotypes
for T13 and T18 in which the affected foetuses often die in the uterus or within the first few
years of life as compared to T21 affected foetuses.
Subsequently Gene Ontology enrichment analysis showed for CVS T13 DMC’s that among
the gene functions of the nearest genes, there was no significant overrepresentation of specific
functions compared to the reference gene set. In contrast, among the functions of the nearest
gene to the CVS T18 DMC’s, there was a highly significant overrepresentation of gene functions
related to regulation of RNA polymerase II mediated transcription and sequence-specific DNA
binding related to transcription factor activity. The smaller number of T13 samples does, how-
ever, increase the risk of false negative findings in the GO analysis, but in spite of this we find
the difference in significant GO terms between CVS T18 and CVS T13 interesting. We have at
present no explanation for this difference but as DNAmethylation to some extent can be con-
sidered a weak proxy for gene expression it would be interesting to investigate if there are dif-
ferences in gene expressions of genes involved in regulation of RNA polymerase II mediated
transcription between CVS T18 and CVS T13 samples.
We are aware that caution should be taken in the interpretation of microarray based data
from CVS samples, because the chorionic villi is a heterogeneous mixture of syncytiotropho-
blastic-, cytotrophoblastic-, mesodermal- and fetal endothelial/vascular cells, and the propor-
tion of the different cell populations in the biopsy could be a confounding factor. This is,
however, to our knowledge the first study to date to investigate the methylation landscape in
T13 and T18 placentas. The relatively large number of samples, especially for T13 and T18 pla-
centas, minimizes the risk of random variability and therefore provides a more representative
biological measure. To further limit the risk of confounding factors such as sex and gestational
age we have used gestational–age-matched blood samples with an equal distribution of samples
with male and female fetuses.
Regarding the circulating cell free DNA (cfDNA) we choose to use maternal white blood
cells as a proxy, since cfDNA in plasma from non-pregnant individuals predominantly origi-
nates from hematopoietic cells [13]. Therefore, it is assumed that the maternally derived
cfDNA in blood from pregnant women has the same origin. However, one study has suggested
that for very obese women a substantial fraction of adipose apoptotic DNA could be released
into the maternal systemic circulation [14]. Optimally maternal cfDNA should have been used.
However, the very low cfDNA fraction in blood samples hinders its appliance for microarray
analysis.
Only very few publications have until now looked at methylation in trisomic placental
DNA. However, the observation of a small but significant increase in fraction of hypermethy-
lated CpG sites in placental samples from T21 cases compared to samples of normal placenta,
are in line with two recent publications showing a general hypermethylation across all chromo-
somes in fetal DNA from T21 placentas [8,9]. Furthermore Jin et al. found several of the epige-
netic changes to be conserved across tissues and they proposed that a down regulation of a
group of the TET-family genes known to play an important role in epigenetic regulation could
be responsible for the overall hypermethylation seen in all chromosomes through decreased
DNA demethylation[9,15]. However, we identified only three CVS T21 DMCs using the most
Microarray-Based Analysis of Methylation of 1st Trimester Trisomic Placentas
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lenient criteria (delta β>0.2 & FDR<0.05), suggesting that the methylation differences are
either relatively small or not very consistent. Eckmann-scholz et al. found 464 DMC between
normal and T21 CVS samples, with a delta β>0.2. They applied the same Illumina methyla-
tion arrays as in our study, however only assessing 27.000 CpGs and the number of T21 sam-
ples in their study was only 3[8].
Assessing the overall methylation landscape in relation to the distance to CpG islands, we
found the most highly different methylated CpGs in T18 to be enriched in CpG islands and
decreased in open sea and shores, when compared to the distribution of all the covered CpGs.
However, when investigating the distribution of CVS T18 DMC in relation to transcription start
sites (TSS), we did not find any enrichment of the DMCs in TSS vicinity, indicating that the
CVS T18 DMCs are located at non-promotor associated CpG islands
We have in the present communication provide a detailed methylation analysis of samples
from T13, T18 and T21 placentas and compare them to normal placenta tissues and maternal
blood. We found a substantial number of significant CpG methylation differences in T13 and
T18 placenta DNA compared to T21 placenta DNA. Our data suggests that the genes associ-
ated with CVS T18 DMCs are enriched for biological pathways/processes related to RNA poly-
merase II mediated gene expression. Our findings do not support the idea of using differences
in the specific methylation imprint (or landscape) of T13, T18 or T21 as targets for NIPD.
Supporting Information
S1 Fig. Density plot of methylation level distribution for CpG-sites on different chromo-
somes. X axis represents methylation level as mean β-values. Y axis represents relative density.
Maternal blood cells (MBC) red line, CVS normal blue line, CVS T13 black line, CVS T18 dark
grey line, T121 light grey line.
(EPS)
S2 Fig. Diagnostic quality control plots. The Illumina Infinium HumanMethylation450
Beadchip arrays include several control probes for determining data quality, including sample-
independent controls: staining controls, extension controls, target removal controls and
hybridization controls. Sample-dependent controls: Bisulphite conversion I controls, Bisul-
phite conversion II controls, Specificity I controls, and Specificity II controls, Nonpolymorphic
controls and Negative controls. Diagnostic plots of all control probes, visualized by illumines
genome studios software, are presented for each of the 3 beadchip arrays.
(ZIP)
S3 Fig. Validation of DNAmethylation data reproducibility. Four replicate samples, two
maternal blood samples (MBC) and two CVS-samples, underwent independent bisulphite con-
version and were analyzed on different beadchip arrays for the validation of DNA methylation
data reproducibility. The figure shows hierarchical clustering and heatmap of correlation coef-
ficients based on all 472K methylation sites. The four replicates MBC3, MBC6, CNOR3 and
CNOR5 all shows the highest correlation between all samples.
(PDF)
S4 Fig. Density scatter plots of the four replicates. All four replicates have a correlation
coefficient> 0.99 for all methylation sites.
(JPG)
S5 Fig. Reproducibility and completeness of bisulphite conversion of unmethylated sites.
The figure shows the mean delta β values for all unmethylated sites (average β< 0.2) for the
four replicates. Since the replicates underwent independent bisulphite conversion, complete
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bisulphite conversion of unmethylated sites should results in reproducible low beta values. A.
Delta β values for all unmethylated sites for the two maternal blood cell (MBC) replicate sam-
ples. Sorted with decreasing delta β values. X axis represents the numbers of unmethylated
sites. B. The distribution of the 100 highest delta β values for the MBC samples. C. Delta β val-
ues for all unmethylated sites for the two CVS replicate samples (CNOR). D. The distribution
of the 100 highest delta β values for the CVS samples.
(PDF)
S6 Fig. Scatterplot displaying data reproducibility of highly polymorphic single nucleotide
polymorphisms (SNPs). The beadchip encompass 65 highly polymorphic single nucleotide
polymorphisms (SNPs) The scatterplot displays the β-values for 65 polymorphic SNPs for the
four replicate samples. Spearman correlation coefficient (ρ) for each pair of replicates is shown.
Diagonal red line represents complete correlation (ρ = 1.00). Methylation levels (β-value) of
0,0, 0.5, and 1.0 shows clear distinct patterns of homozygous or heterozygous methylation.
(EPS)
S1 Table. Overview of all samples used in the methylation analysis. The table lists samples,
fetal gender, year of sampling, sample material, chromosome analysis, gestational age (weeks),
and maternal age (in years).
(DOCX)
S2 Table. Gene Ontology (GO) analyses related to CVS T18 DMCs. Gene functions related
to terms within the group “Biological processes”. The table shows the enrichment analysis for
the genes associated to our DMCs in T18 samples. The total number of genes within the GO
analysis is 17727. Our gene set related to the CVS T18 DMCs were 118.
(XLS)
S3 Table. Overview of the methylation differences between replicates. Numbers (and per-
centages) of sites with increasing delta β value thresholds. A All methylation sites. B Unmethy-
lated Sites (average delta β< 0.2).
(PDF)
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